BeiGene: Clinical Trials

101 trials sponsored by BeiGene, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

48 completed, 19 recruiting, 9 active not recruiting, 9 unknown. 101 Phase 2, 20 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2101Completed 48, Recruiting 19, Active not recruiting 9, Unknown 9, Terminated 7, Withdrawn 5, Not yet recruiting 4
Phase 120Completed 10, Terminated 3, Active not recruiting 2, Recruiting 2, Unknown 2, Not yet recruiting 1

Follow BeiGene: new trials by email

Trials (filtered) newest first · largest first

All 101 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Sonrotoclax Plus Azacitidine in Patients With MDS-IB2
Sonrotoclax, Azacitidine (AZA) - Myelodysplastic Syndromes, High Risk
Phase 1 / Phase 2RecruitingShanghai General Hospital, Shanghai Jiao Tong University School of Medicine602026-10-152026-10-21
Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia
zanubrutinib + BGB-11417 - Waldenstrom Macroglobulinemia
Phase 2Not yet recruitingFrench Innovative Leukemia Organisation1022025-12-012025-11-26
A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC
Tislelizumab + Anlotinib - SCLC, Limited Stage
Phase 2RecruitingYantai Yuhuangding Hospital202025-11-042026-09-11
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
Zanidatamab, Tislelizumab, Cisplatin - Muscle Invasive Bladder Cancer (MIBC)
Phase 2RecruitingFujian Medical University Union Hospital252025-10-252025-12-22
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
Tislelizumab, Paclitaxel, Cisplatin - Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer
Phase 2RecruitingMing-Yu Lien452025-09-262026-02-27
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
Tislelizumab, Fruquintinib - Minimal Residual Disease, Adjuvant Chemotherapy
Phase 2Active not recruitingM.D. Anderson Cancer Center152025-09-182026-08-12
A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis
BGB-45035, Placebo - Rheumatoid Arthritis
Phase 2TerminatedBeiGene492025-08-212026-05-28
Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma
Tislelizumab, Paclitaxel, Cisplatin - ESCC, Total Neoadjuvant Treatment
Phase 2RecruitingNational Taiwan University Hospital502025-07-232026-01-27
Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer
Tislelizumab & Fruquintinib - Metastatic Colorectal Cancer, mCRC
Phase 2WithdrawnSun Yat-sen University2025-07-012024-07-09
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
Glofitamab, Polatuzumab Vedotin, Zanubrutinib - Diffuse Large B-Cell Lymphoma
Phase 2RecruitingShanghai Zhongshan Hospital382025-06-202026-10-16
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
Bendamustine, Rituximab, Cytarabine - Mantle Cell Lymphoma, Lymphoma
Phase 2RecruitingChristine Ryan602025-04-222026-02-20
Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma
Obinutuzumab, Glofitamab, Venetoclax Oral Product - Lymphoma, Mantle-Cell
Phase 2RecruitingThe Lymphoma Academic Research Organisation1002025-02-212026-07-10
A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis
HIPEC, SOX, Immune Checkpoint Inhibitors - Gastric Cancer
Phase 2RecruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology342025-02-152025-04-11
Epco, Zanu, Ritux for R/R FL or MZL
Zanubrutinib, Rituximab, Epcoritamab - Follicular Lymphoma, Lymphoma
Phase 2RecruitingReid Merryman, MD712025-01-212026-09-25
Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia
sonrotoclax, idarubicin/daunorubicin, Cytarabine - Acute Myeloid Leukemia
Phase 2Active not recruitingShanghai Jiao Tong University School of Medicine472024-10-302026-04-30
A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.
Distitamab Vedotin in combination with Tislelizumab - NMIBC
Phase 2Not yet recruitingFujian Medical University Union Hospital402024-10-012024-10-10
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
Trametinib, Anlotinib, Tislelizumab - KRAS Mutation-Related Tumors, Advanced Lung Cancer
Phase 1 / Phase 2Not yet recruitingShanghai Chest Hospital602024-07-012024-06-13
Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma
Zanubrutinib, Rituximab - Mantle Cell Lymphoma
Phase 2RecruitingUniversity College, London502024-05-172025-04-16
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
Pemetrexed, Zanubrutinib, Autologous Stem Cell Transplant (ASCT) - Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Phase 2RecruitingBaptist Health South Florida152024-04-252026-03-03
Zanubrutinib Treatment in Patients With IgM Monoclonal Gammopathy and Antri-MAG Related Polyneuropathy
Zanubrutinib Oral Product - Monoclonal Gammopathy of Uncertain Significance
Phase 2Active not recruitingUMC Utrecht352024-03-012026-05-08

Showing 20 of 101. Sign in to see all of them.

Conditions studied

Leukemia, Lymphocytic, Chronic, B-Cell (7)  ·  Lymphoma, Large B-Cell, Diffuse (7)  ·  Lymphoma, Mantle-Cell (7)  ·  Colorectal Neoplasms (6)  ·  Lymphoma, B-Cell, Marginal Zone (6)  ·  Stomach Neoplasms (6)  ·  Carcinoma, Non-Small-Cell Lung (5)  ·  Esophageal Squamous Cell Carcinoma (5)  ·  Lymphoma, Follicular (5)  ·  Lymphoma (4)  ·  Neoplasms (4)  ·  Recurrence (4)  ·  Waldenstrom Macroglobulinemia (4)  ·  Carcinoma, Hepatocellular (3)  ·  Esophageal Neoplasms (3)

Interventions

tislelizumab (58)  ·  zanubrutinib (24)  ·  Cisplatin (9)  ·  Paclitaxel (8)  ·  pamiparib (7)  ·  Carboplatin (6)  ·  Pemetrexed (6)  ·  Docetaxel (5)  ·  Rituximab (5)  ·  sitravatinib (5)  ·  HMPL-013 (4)  ·  Capecitabine (3)  ·  Chemoradiotherapy (3)  ·  Fluorouracil (3)  ·  Gemcitabine (3)

Countries

China (61)  ·  United States (31)  ·  South Korea (18)  ·  Australia (13)  ·  France (13)  ·  Spain (12)  ·  Taiwan (12)  ·  Italy (9)  ·  United Kingdom (8)  ·  Canada (5)  ·  Thailand (5)  ·  New Zealand (4)  ·  Poland (4)  ·  Brazil (3)  ·  Czechia (3)

Top investigators

Alison Freimund (1)  ·  Arvind Dasari, MD (1)  ·  Baohui Han, MD, PhD (1)  ·  Brian Shuch, MD (1)  ·  Christine Ryan, MD (1)  ·  Cynthia Sirard, MD (1)  ·  David Schiff, MD (1)  ·  Do-Youn Oh, M.D., PhD. (1)  ·  Herve Ghesguieres (1)  ·  Inhye E Ahn, MD (1)  ·  Jeff Goh, MBBS, FRACP (1)

Results publications

PMID 38502198, PMID 38775302, PMID 34152395, PMID 35900694, PMID 36879284, PMID 22919026, PMID 26770954, PMID 28034070, PMID 28188133, PMID 28486951, PMID 28879531, PMID 28911074, PMID 29386072, PMID 31520078, PMID 32393328, PMID 32461234, PMID 32561664, PMID 33047430, PMID 33332484, PMID 33827139, PMID 34473343, PMID 34702811, PMID 34716199, PMID 35303070, PMID 35390135, PMID 36400069, PMID 36797356, PMID 36799536, PMID 36820098, PMID 36922805, PMID 37276067, PMID 37276871, PMID 37506346, PMID 37682792, PMID 37699634, PMID 38650037, PMID 39114870, PMID 39376156, PMID 39432867, PMID 39563886, PMID 39624833, PMID 39762418, PMID 39906744, PMID 39978682, PMID 40008672, PMID 40334067, PMID 40341124, PMID 40411966, PMID 40812353, PMID 41202501

NIH funding

2017 (4), 2018 (3), 2023 (2), 2016 (1), 2019 (1), U10CA180888 (1), UM1CA137443 (1)